abiraterone has been researched along with epothilone a in 2 studies
| Studies (abiraterone) | Trials (abiraterone) | Recent Studies (post-2010) (abiraterone) | Studies (epothilone a) | Trials (epothilone a) | Recent Studies (post-2010) (epothilone a) |
|---|---|---|---|---|---|
| 942 | 97 | 854 | 904 | 144 | 360 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albiges, L; Blesius, A; de La Motte Rouge, T; Escudier, B; Fizazi, K; Gross-Goupil, M; Loriot, Y; Massard, C | 1 |
| Redding, MB; Surati, M | 1 |
2 other study(ies) available for abiraterone and epothilone a
| Article | Year |
|---|---|
[New drugs in metastatic castration-resistant prostate cancer].
Topics: Androgen Antagonists; Androstenes; Androstenols; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Bone Neoplasms; Castration; Denosumab; Epothilones; ErbB Receptors; Furans; Humans; Immunotherapy; Ketones; Male; Orchiectomy; Prostatic Neoplasms; Pyrrolidines; RANK Ligand | 2010 |
Emerging treatments for castrate-resistant prostate cancer.
Topics: Androstenes; Androstenols; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Clinical Trials as Topic; Epothilones; Humans; Male; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Tubulin Modulators | 2011 |